{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:46:01Z","timestamp":1790142361226,"version":"4.0.1"},"reference-count":58,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2010,6,3]],"date-time":"2010-06-03T00:00:00Z","timestamp":1275523200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0010941","type":"journal-article","created":{"date-parts":[[2010,6,3]],"date-time":"2010-06-03T20:43:59Z","timestamp":1275597839000},"page":"e10941","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":49,"title":["The Novel Deacetylase Inhibitor AR-42 Demonstrates Pre-Clinical Activity in B-Cell Malignancies In Vitro and In Vivo"],"prefix":"10.1371","volume":"5","author":[{"given":"David M.","family":"Lucas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lapo","family":"Alinari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek A.","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie E.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan B.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy J.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristie A.","family":"Blum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig C.","family":"Hofmeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Freitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Parthun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dasheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Lehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Jarjoura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel K.","family":"Kulp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo M.","family":"Croce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Grever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Shih","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Baiocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2010,6,3]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1073\/pnas.0430973100","article-title":"Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation.","volume":"100","author":"SJ Haggarty","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"26729","DOI":"10.1074\/jbc.C500186200","article-title":"Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.","volume":"280","author":"P Bali","year":"2005","journal-title":"J Biol Chem"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.molcel.2005.04.021","article-title":"HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor.","volume":"18","author":"JJ Kovacs","year":"2005","journal-title":"Mol Cell"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors.","volume":"5","author":"JE Bolden","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/CCO.0b013e3283127095","article-title":"Histone deacetylase inhibitors in cancer therapy.","volume":"20","author":"MJ Lee","year":"2008","journal-title":"Curr Opin Oncol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/annonc\/mdn792","article-title":"HDAC inhibitor-based therapies and haematological malignancy.","volume":"20","author":"L Stimson","year":"2009","journal-title":"Ann Oncol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","article-title":"Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.","volume":"27","author":"RL Piekarz","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.","volume":"25","author":"EA Olsen","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"iv12","DOI":"10.1093\/annonc\/mdj992","article-title":"Mantle cell lymphoma: an update on management.","volume":"17","author":"AD Zelenetz","year":"2006","journal-title":"Ann Oncol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1182\/blood-2002-12-3794","article-title":"Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein.","volume":"102","author":"JL Aron","year":"2003","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2004-05-1693","article-title":"A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.","volume":"105","author":"JC Byrd","year":"2005","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1182\/blood.V94.4.1401","article-title":"Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells.","volume":"94","author":"JC Byrd","year":"1999","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.exphem.2007.06.014","article-title":"Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response.","volume":"35","author":"L Lagneaux","year":"2007","journal-title":"Exp Hematol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/sj.leu.2403388","article-title":"The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells.","volume":"18","author":"DM Lucas","year":"2004","journal-title":"Leukemia"},{"key":"ref15","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2141.2009.07881.x","article-title":"Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia.","author":"KA Blum","year":"2009"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1021\/jm0503749","article-title":"Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors.","volume":"48","author":"Q Lu","year":"2005","journal-title":"J Med Chem"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1021\/jm0303655","article-title":"Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors.","volume":"47","author":"Q Lu","year":"2004","journal-title":"J Med Chem"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"938","DOI":"10.2460\/ajvr.69.7.938","article-title":"Evaluation of the effects of histone deacetylase inhibitors on cells from canine cancer cell lines.","volume":"69","author":"WC Kisseberth","year":"2008","journal-title":"Am J Vet Res"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"5199","DOI":"10.1158\/1078-0432.CCR-06-0429","article-title":"Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer.","volume":"12","author":"SK Kulp","year":"2006","journal-title":"Clin Cancer Res"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/hep.21804","article-title":"Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma.","volume":"46","author":"YS Lu","year":"2007","journal-title":"Hepatology"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1158\/0008-5472.CAN-08-0203","article-title":"OSU-HDAC42, a histone deacetylase inhibitor, blocks prostate tumor progression in the transgenic adenocarcinoma of the mouse prostate model.","volume":"68","author":"AM Sargeant","year":"2008","journal-title":"Cancer Res"},{"key":"ref22","author":"TY Lin"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood-2006-05-020735","article-title":"Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia.","volume":"109","author":"JC Byrd","year":"2007","journal-title":"Blood"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1182\/blood.V96.5.1926","article-title":"Stromal cells regulate survival of B-lineage leukemic cells during chemotherapy.","volume":"96","author":"RE Mudry","year":"2000","journal-title":"Blood"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1182\/blood-2004-03-0889","article-title":"Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha.","volume":"106","author":"M Nishio","year":"2005","journal-title":"Blood"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1365-2141.1996.00305.x","article-title":"Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro.","volume":"92","author":"P Panayiotidis","year":"1996","journal-title":"Br J Haematol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1182\/blood.V85.4.997.bloodjournal854997","article-title":"Functionally distinct human marrow stromal cell lines immortalized by transduction with the human papilloma virus E6\/E7 genes.","volume":"85","author":"BA Roecklein","year":"1995","journal-title":"Blood"},{"key":"ref28","first-page":"3697","article-title":"Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial\/cytochrome c-dependent pathway.","volume":"57","author":"V Medina","year":"1997","journal-title":"Cancer Res"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2002-11-3514","article-title":"Molecular sequelae of histone deacetylase inhibition in human malignant B cells.","volume":"101","author":"N Mitsiades","year":"2003","journal-title":"Blood"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"8567","DOI":"10.1073\/pnas.0503221102","article-title":"Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma.","volume":"102","author":"T Hideshima","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/417455a","article-title":"HDAC6 is a microtubule-associated deacetylase.","volume":"417","author":"C Hubbert","year":"2002","journal-title":"Nature"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"17102","DOI":"10.1074\/jbc.M809090200","article-title":"Tubacin kills Epstein-Barr virus (EBV)-Burkitt lymphoma cells by inducing reactive oxygen species and EBV lymphoblastoid cells by inducing apoptosis.","volume":"284","author":"J Kawada","year":"2009","journal-title":"J Biol Chem"},{"key":"ref33","first-page":"521","article-title":"Histone deacetylase inhibitors sensitize human colonic adenocarcinoma cell lines to TNF-related apoptosis inducing ligand-mediated apoptosis.","volume":"9","author":"H Inoue","year":"2002","journal-title":"Int J Mol Med"},{"key":"ref34","first-page":"1273","article-title":"Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells.","volume":"2","author":"RR Rosato","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1158\/0008-5472.CAN-05-4563","article-title":"Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.","volume":"66","author":"S Inoue","year":"2006","journal-title":"Cancer Res"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1038\/sj.cdd.4401535","article-title":"Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies.","volume":"11","author":"S Inoue","year":"2004","journal-title":"Cell Death Differ"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"6809","DOI":"10.1038\/sj.onc.1205853","article-title":"Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia.","volume":"21","author":"M MacFarlane","year":"2002","journal-title":"Oncogene"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/0145-2126(94)90089-2","article-title":"The C.B.17 scid mouse strain as a model for human disseminated leukaemia and myeloma in vivo.","volume":"18","author":"AR Cattan","year":"1994","journal-title":"Leuk Res"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"424","DOI":"10.5858\/2003-127-0424-COMCLC","article-title":"Characterization of 4 mantle cell lymphoma cell lines.","volume":"127","author":"HM Amin","year":"2003","journal-title":"Arch Pathol Lab Med"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1046\/j.1365-2141.1998.00911.x","article-title":"Establishment and characterization of a mantle cell lymphoma cell line.","volume":"102","author":"HJ Jeon","year":"1998","journal-title":"Br J Haematol"},{"key":"ref41","article-title":"FTY720 demonstrates promising in-vitro and in-vivo Pre-clinical Activity by Down-modulating Cyclin D1 and phospho-Akt in Mantle Cell Lymphoma.","author":"Q Liu","year":"2010"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.1073\/pnas.102181599","article-title":"Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression.","volume":"99","author":"R Bichi","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1182\/blood-2005-12-011213","article-title":"Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia.","volume":"108","author":"AJ Johnson","year":"2006","journal-title":"Blood"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.4049\/jimmunol.0801847","article-title":"Tumoricidal effects of activated macrophages in a mouse model of chronic lymphocytic leukemia.","volume":"182","author":"QL Wu","year":"2009","journal-title":"J Immunol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1182\/blood-2009-07-233718","article-title":"Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance.","volume":"114","author":"AV Kurtova","year":"2009","journal-title":"Blood"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1067\/msy.2001.115897","article-title":"Butyrate sensitizes human colon cancer cells to TRAIL-mediated apoptosis.","volume":"130","author":"A Hernandez","year":"2001","journal-title":"Surgery"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"5411","DOI":"10.1158\/1078-0432.CCR-07-0791","article-title":"Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies.","volume":"13","author":"S Kummar","year":"2007","journal-title":"Clin Cancer Res"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1365-2141.2009.07881.x","article-title":"Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia.","volume":"147","author":"KA Blum","year":"2009","journal-title":"Br J Haematol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1073\/pnas.0500369102","article-title":"Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors.","volume":"102","author":"MJ Peart","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/nrm2346","article-title":"The Rpd3\/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men.","volume":"9","author":"XJ Yang","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"2571a","DOI":"10.1182\/blood.V110.11.2571.2571","article-title":"Treatment of relapsed or refractory lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: Interim results from a Phase II study.","volume":"118","author":"A Younes","year":"2007","journal-title":"Blood"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"2566a","DOI":"10.1182\/blood.V110.11.2566.2566","article-title":"Isotype-selective HDAC inhibitor MGCD0103 decreases serum TARC concentrations and produces clinical responses in heavily pretreated patients with relapsed classical Hodgkin Lymphoma.","volume":"110","author":"A Younes","year":"2007","journal-title":"Blood"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.2005.01.9679","article-title":"Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.","volume":"24","author":"OA O'Connor","year":"2006","journal-title":"J Clin Oncol"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"1564a","DOI":"10.1182\/blood.V112.11.1564.1564","article-title":"A Phase 2 study of vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in relapsed or refractory indolent Non-Hodgkin's Lymphoma. A California Cancer Consortium study.","volume":"112","author":"M Kirschbaum","year":"2008","journal-title":"Blood"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2141.2009.07837.x","article-title":"Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma.","volume":"147","author":"M Dickinson","year":"2009","journal-title":"Br J Haematol"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1182\/blood-2007-06-098061","article-title":"Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.","volume":"111","author":"G Garcia-Manero","year":"2008","journal-title":"Blood"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1182\/blood-2008-09-175430","article-title":"The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo.","volume":"113","author":"DM Lucas","year":"2009","journal-title":"Blood"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1084\/jem.178.3.1103","article-title":"Selective long-term elimination of natural killer cells in vivo by an anti-interleukin 2 receptor beta chain monoclonal antibody in mice.","volume":"178","author":"T Tanaka","year":"1993","journal-title":"J Exp Med"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0010941","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T21:41:30Z","timestamp":1635457290000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0010941"}},"subtitle":[],"editor":[{"given":"Alfons","family":"Navarro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2010,6,3]]},"references-count":58,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2010,6,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0010941","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,3]]}}}